Navigation Links
Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
Date:12/1/2008

t, rotating and early riser), travel across time zones, delayed sleep phase syndrome, advanced phase syndrome and the non-24-hour sleep-wake syndrome in the blind. These disorders represent a large public health problem and, as presented in the 2006 Institute of Medicine (IOM) report on sleep disorders(5), the annual economic impact of sleep problems due to night shift work alone is estimated to exceed $65 billion.

The novel circadian regulator tasimelteon holds promise for the treatment of patients with misalignments of the body clock. The work presented in The Lancet examines the potential application in sleep disorders. Additional clinical trials will have to be conducted to examine the role of circadian regulators in the treatment of other disorders such as depression, nondipper hypertension(3)(4), and others.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," and "could," and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: delays in the completion of Vanda's clinical trials; a failure of Vanda's product candidates to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda's product candidates in the marketplace, or a failur
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
2. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
3. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
4. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
5. Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma
6. CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease
7. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
8. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
9. Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
10. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
11. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel wearable injector ... easy and painless for patients to self-inject prescription drugs in ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   Many ...
(Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... 7, 2011 CareFusion Corporation (NYSE: ... today the appointment of Carlos M. Nunez, M.D. as its ... an anesthesiologist, intensivist and hospitalist as well as an experienced ... business career in the areas of clinical effectiveness, information technology, ...
... CHICAGO, March 7, 2011 General Nutrition Company (GNC) ... products manufacturer Sakar International for a line of more ... line,s initial merchandise offerings will range from heart rate ... and electronic pill boxes. The products ...
Cached Medicine Technology:CareFusion Appoints Carlos M. Nunez, M.D. as Chief Medical Officer 2GNC Teams With Sakar International for Branded Health and Wellness Product Line 2GNC Teams With Sakar International for Branded Health and Wellness Product Line 3
(Date:4/24/2014)... professor in the new Institute for Biomedical Sciences ... $2.83 million federal grant to develop novel therapeutics ... grant from the Eunice Kennedy Shriver National Institute ... National Institutes of Health will support Plemper,s drug ... at least one distinct alternative compound. , Infections ...
(Date:4/24/2014)... epidemic of prescription opioid overdose deaths was outlined yesterday ... by leaders of agencies in the U.S. Department of ... health care providers to expand their use of medications ... describes a number of misperceptions that have limited access ... how medications can be used in combination with behavior ...
(Date:4/24/2014)... was the first in the world to discover a ... the jaw. , Ameloblastoma is an odontogenic tumour with ... most often found in the posterior of the lower ... tissue deficiencies in the jaws as well as loss ... the need for surgery and the recurrence of ameloblastoma, ...
(Date:4/24/2014)... Foundation has awarded LSU Health Sciences Center New ... grant in the amount of $295,635. The funding ... social and educational backgrounds, underrepresented in the sciences, ... project will provide students with training for 10 ... will be led by Principal Investigator Dr. Fern ...
(Date:4/23/2014)... General Hospital (MGH) investigators may lead to greater availability ... medical problem use of fecal material from healthy ... Clostridium difficile ( C. difficile ) bacteria. ... Clinical Infectious Diseases , the researchers report that ... to patients was as successful in curing recurrent ...
Breaking Medicine News(10 mins):Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3
... This release is available in German . ... and learning about the warning signs of lymphedema: that,s ... lymphedema, according to the German Institute for Quality and ... about how to protect themselves from this common and ...
... AUGUSTA, Maine, Nov. 6 Building on the ... for small businesses in Maine,the Maine State Chamber ... and Blue Shield have announced further additions to ... January, Chamber,BlueOptions will include eight health plans from ...
... Invisicare Is Put In Place, LAS VEGAS, ... the developers of Invisicare, a patented polymer,delivery system ... of Geert Cauwenbergh, PhD to head its International,Advisory ... expand the demand,for Invisicare in international markets. Dr. ...
... Nov. 6 /Xinhua-PRNewswire-FirstCall/ -- Tianyin,Pharmaceutical, Co., Inc., (Amex: ... traditional Chinese medicine ("TCM") based in Chengdu, China,today ... to discuss its,2009 fiscal first quarter at 8:30 ... will be released that day before the market ...
... A steady march toward using,ever-more "patient-friendly" ... proceedings of the 37th Global Congress of ... international professional society for,specialists in minimally invasive ... preserving the highest possible quality of,life for ...
... People With,Diabetes and Their Caregivers, WESTPORT, Conn., Nov. ... laughter, and family, usually accompanied by trays of cookies,cakes, ... some,of the nearly 24 million people in America with ... dLife helped over 100,000 online,visitors survive the season with ...
Cached Medicine News:Health News:How women can improve their quality of life after breast cancer treatment 2Health News:Chamber BlueOptions Insurance Adds to its Options and Benefits for 2009 Suite of Insurance Plans Meeting Small Business Needs 2Health News:Chamber BlueOptions Insurance Adds to its Options and Benefits for 2009 Suite of Insurance Plans Meeting Small Business Needs 3Health News:Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board 2Health News:Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board 3Health News:Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 First Quarter Earnings Conference Call on Tuesday, November 11, 2008 at 8:30 a.m. EST 2Health News:Hi-Tech Advances the Practice of Minimally Invasive Gynecology at AAGL Global Congress 2Health News:Hi-Tech Advances the Practice of Minimally Invasive Gynecology at AAGL Global Congress 3Health News:Hi-Tech Advances the Practice of Minimally Invasive Gynecology at AAGL Global Congress 4Health News:Back By Popular Demand - dLife Holiday Helpline 2
... System 9700 can now be used with ... The aluminum block has been designed for ... sequencing in a conventional 8 X 12 ... system to be used in 9600 emulation ...
96 well thermocycler with unique High Temperature Range (HTR) Peltier technology for fastest available heating and cooling rates up to 4C/sec with High Pressure Lid for automated sealing of PCR plate...
... for day-to-day temperature cycling ... 0.1C ,30% reduction in ... or coolant-based cyclers ,4 ... ramping ,Options for oil-free ...
... TC-512 has a graphical touch screen display ... at the "touch of a screen." ... gradient, Touch Screen, Graphical Display, Memory Cards, ... Block Format, Intuitive Programmin, Free Instrument Software ...
Medicine Products: